NRG-GY018

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Contact phone
Clinical Trials Office 517-364-9400
Principal investigator
Gordan Srkalovic, MD, PhD
Trial Category
Cancer
Trial SubCategory
Endometrial